难治性丙型肝炎研究进展  

Research Progress of Refractory Hepatitis C

作　　者：李红玉[1] 薛博瑜[1] 

机构地区：[1]南京中医药大学,江苏南京210046

出　　处：《辽宁中医杂志》2014年第1期176-178,共3页Liaoning Journal of Traditional Chinese Medicine

基　　金：国家科技重大专项(2008ZX10005-009)

摘　　要：直接抗病毒药物的出现提高了难治性丙肝患者的持续病毒学应答率,但是由于其价格高昂导致接受治疗的患者有限,加之病毒变异、耐药性、副作用及患者依从性差等,再加上我国许多地区对丙型肝炎筛查不足,使我国许多难治性丙肝患者不能得到及早发现以及有效的抗病毒治疗,致使病情进展。故而寻求安全、有效、低成本、具有良好耐受性的治疗方案和药物,是我国未来治疗难治性丙型肝炎关注的重点。文章综述了难治性丙型肝炎的治疗进展,包括直接抗病毒药物的疗效及安全,以及中医对本病的病因病机认识、中西医结合治疗情况。The emergence of direct antiviral drugs increased the sustained virologic response rate of patients with refractory hepatitis C, however many patients with refractory hepatitis C can not be early detected and effective treatment and resulting in disease progression, due to its high price, the virus mutation, drug resistance, side effects and poor patient compliance, coupled with lacking of screening for hepatitis C in many regions. Therefore, the focus on treating refractory hepatitis C is to find safe, ef- fective,low - cost, well - tolerated treatment programs and drugs. Here we review the progress of refractory hepatitis C, including the efficacy and safety of direct antiviral drugs and the understanding of the etiology and its etiology and pathogenesis and treat- ment in traditional Chinese medicine.

关 键 词：难治性丙型肝炎 研究进展 中医药 直接抗病毒药物 

分 类 号：R512.63[医药卫生—内科学]